WO2024214088 - HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS
National phase entry:
Publication Number
WO/2024/214088
Publication Date
17.10.2024
International Application No.
PCT/IB2024/053673
International Filing Date
15.04.2024
Title **
[English]
HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS
[French]
COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DOUBLES DE PD-L1 ET DE RÉCEPTEURS D'ADÉNOSINE
Applicants **
AURIGENE ONCOLOGY LIMITED
39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road,
Bangalore 560100, IN
Inventors
VENKATESHAPPA, Chandregowda
No 709, 1st Main, 5th Cross, RHCS
Layout, Srigandakaval, Nagarabhavi
Bangalore 560091, IN
SAMAJDAR, Susanta
Flat # R801, H. M Tambourine, Jaraganahalli, J.P. Nagar 6th Phase
Bangalore 560078, IN
PUTTA, V P Rama Kishore
Flat No: D-102, LIC HFL Care
Homes, Madanayakanahalli
Bangalore 562162, IN
Priority Data
202321027615
14.04.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2969 | |
| EPO | Filing, Examination | 17360 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 10610 |
Total: 32104 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application relates to heterocyclic compounds represented by compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof which are useful as dual inhibitors of PD-L1 and Adenosine receptors (A2AR). The present application also relates to pharmaceutical compositions comprising said compounds or a pharmaceutically acceptable salt or a stereoisomer thereof and use of such compounds in the treatment of diseases mediated by PD-L1 and A2AR.[French]
La présente demande concerne des composés hétérocycliques représentés par le composé de formule (I), un sel pharmaceutiquement acceptable ou un stéréoisomère de celui-ci qui sont utiles en tant qu'inhibiteurs doubles de PD-L1 et de récepteurs d'adénosine (A2AR). La présente demande concerne également des compositions pharmaceutiques comprenant lesdits composés, un sel pharmaceutiquement acceptable ou un stéréoisomère de ceux-ci et l'utilisation de tels composés dans le traitement de maladies médiées par PD-L1 et A2AR.